RINVOQ Drug Insight and Market Forecast – 2032

RINVOQ Drug Insight and Market Forecast – 2032

“RINVOQ Drug Insight and Market Forecast – 2032” report provides comprehensive insights about RINVOQ for Rheumatoid Arthritis in the 7MM. A detailed picture of the RINVOQ for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the RINVOQ for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RINVOQ market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.

Drug Summary

RINVOQ, an AbbVie product, is a prescription medicine used to treat adults with moderate-to-severe RA in whom methotrexate did not work well or could not be tolerated.

The approval granted to RINVOQ was on the basis of its Phase III (SELECT-COMPARE) clinical trials, where it met all primary and ranked secondary endpoints. Within the time frame of only 9 months after its launch in the market, it has become the first choice of rheumatologists, who now select RINVOQ as their JAK of choice if limited to just one for the treatment of RA. Indeed, rheumatologists report that more than one in five of their JAK-treated RA patients are currently prescribed RINVOQ, and six-month projections call for this figure to double.

 Mechanism of Action

Upadacitinib is a JAK inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs), which modulate intracellular activity, including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, and JAK2/TYK2). In a cell-free, isolated enzyme assay, upadacitinib had greater inhibitory potency at JAK1 and JAK2 relative to JAK3 and TYK2. In human leukocyte cellular assays, upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

 Dosage and Administration

The recommended oral dose of RINVOQ is 15 mg once daily with or without food, RINVOQ may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the RINVOQ description, mechanism of action, dosage and administration, research and development activities in Rheumatoid Arthritis.

Elaborated details on RINVOQ regulatory milestones and other development activities have been provided in this report.

The report also highlights the RINVOQ research and development activity in Rheumatoid Arthritis details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around RINVOQ.

The report contains forecasted sales of RINVOQ for Rheumatoid Arthritis till 2032.

Comprehensive coverage of the late-stage emerging therapies for Rheumatoid Arthritis.

The report also features the SWOT analysis with analyst views for RINVOQ in Rheumatoid Arthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RINVOQ Analytical Perspective by DelveInsight

In-depth RINVOQ Market Assessment

This report provides a detailed market assessment of RINVOQ in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

RINVOQ Clinical Assessment

The report provides the clinical trials information of RINVOQ for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Rheumatoid Arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RINVOQ dominance.

Other emerging products for Rheumatoid Arthritis are expected to give tough market competition to RINVOQ and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RINVOQ in Rheumatoid Arthritis.

Our in-depth analysis of the forecasted sales data of RINVOQ from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RINVOQ in Rheumatoid Arthritis.

Key Questions

What is the product type, route of administration and mechanism of action of RINVOQ?

What is the clinical trial status of the study related to RINVOQ in Rheumatoid Arthritis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RINVOQ development?

What are the key designations that have been granted to RINVOQ for Rheumatoid Arthritis?

What is the forecasted market scenario of RINVOQ for Rheumatoid Arthritis?

What are the forecasted sales of RINVOQ in the 7MM, including the United States, Europe, and Japan?

What are the other emerging products available in Rheumatoid Arthritis and how are they giving competition to RINVOQ for Rheumatoid Arthritis?

Which are the late-stage emerging therapies under development for the treatment of Rheumatoid Arthritis?